48,833
edits
Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"
Jump to navigation
Jump to search
Classification of urothelial carcinoma by immunohistochemistry (view source)
Revision as of 18:46, 15 October 2021
, 18:46, 15 October 2021→General
| Line 3: | Line 3: | ||
==General== | ==General== | ||
*A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |vauthors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | *A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |vauthors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | ||
===A simple classification of urothelial carcinoma by immunohistochemistry=== | ===A simple classification of urothelial carcinoma by immunohistochemistry=== | ||